References
1.Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003; 300:1763-7. Published online May 13, 2003. http://www.sciencemag.org/cgi/content/full/300/5626/1763
2.Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. J Virol 2000; 74:8913-21. http://jvi.asm.org/cgi/content/full/74/19/8913
3.Breiman RF, Evans MR, Preiser W, et al. Role of China in the Quest to Define and Control Severe Acute Respiratory Syndrome. Emerg Infect Dis Vol. 9, No. 9, 2003 Sep. Soon available from: http://www.cdc.gov/ncidod/EID/upcoming.htm.
4.Breiman RF, Evans MR, Preiser W, et al. Role of China in the Quest to Define and Control Severe Acute Respiratory Syndrome. Emerg Infect Dis 2003; 9(9):1037-41. Available from: http://www.cdc.gov/ncidod/EID/vol9no9/03-0390.htm
5.Brown EG, Tetro JA. Comparative analysis of the SARS coronavirus genome: a good start to a long journey. Lancet 2003; 361:1756-7.
6.Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003a; 361:2045-6. http://SARSReference.com/link.php?id=12814717
7.Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet 2003b; 362:293-294. http://sarsreference.com/link.php?id=12892961
8.Cyranoski D, Abbott A. Virus detectives seek source of SARS in China's wild animals. Nature 2003; 423:467.
9.Drosten C, Gunther S, Preiser W, et al. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. N Engl J Med 2003a; 348:1967-76. Published online Apr 10, 2003. http://SARSReference.com/lit.php?id=12690091
- April 8-10
- April 12
- June 6
- August 14
- September 8
- September 24
- References
- 30 Virology
- Discovery of the SARS Virus
- Initial Research
- Coronaviridae
- SARS Co-V
- Genome Sequence
- Antiviral Agents and Vaccines
- Antiviral Drugs
- Vaccines
- Outlook
- References
- Routes of Transmission
- Patient Factors in Transmission
- Asymptomatic Patients
- Symptomatic Patients
- The Unsuspected Patients
- High-Risk Activities
- Transmission during Quarantine
- Introduction
- Global Spread
- Hong Kong
- Other Countries
- Eradication
- Outlook
- Introduction
- International Coordination
- Management of SARS in the post-outbreak period
- National Measures
- Legislation
- Quarantine after Discharge
- Infection Control in Healthcare Settings
- General Measures
- Protective Measures
- Special Settings
- Intensive Care Units
- Intubating a SARS Patient
- Anesthesia
- Triage
- Internet Sources
- After the Outbreak
- Conclusion
- 108 Case Definition
- WHO Case Definition
- Suspect case
- Reclassification of cases
- CDC Case Definition
- 112 Diagnostic Tests
- Introduction
- Laboratory tests
- Virus isolation
- Antibody detection
- Interpretation
- Limitations
- Biosafety considerations
- Clinical Presentation and Diagnosis
- Clinical Presentation
- Diagnosis
- Clinical Course
- Histopathology
- Lung Biopsy
- Postmortem Findings
- Discharge and Follow-up
- Psychosocial Issues
- References
- 144 SARS Treatment
- Antibiotic therapy
- Antiviral therapy
- Ribavirin
- Alternative medicine
- Immunomodulatory therapy
- Other immunomodulators
- Assisted ventilation
- Invasive mechanical ventilation
- Clinical outcomes
- Appendix 1
- A standardized treatment protocol for adult SARS in Hong Kong
- Appendix 2
- A treatment regimen for SARS in Guangzhou, China
- References
- 168 Pediatric SARS
- Clinical Manifestation